Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma

Trial Profile

Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs CVA 21 (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms CAPRA
  • Sponsors Viralytics
  • Most Recent Events

    • 05 Apr 2017 Primary endpoint (Statistical futility endpoint: achieving 2 confirmed objective responses (CR or PR) in the first 12 patients enrolled) has been met, according to interim results presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 05 Apr 2017 Planned number of patients changed from 30 to 50, according to interim results presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 05 Apr 2017 Interim results (n=14,pre-specified futility analysis), presented at the 108th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top